Multiple sclerosis (MS) is a chronic inflammatory demyelinating central nervous system
disease that typically strikes young adults, especially women. The pathobiology of MS …

Immunomodulatory and immunosuppressive treatments for multiple sclerosis (MS) are
associated with an increased risk of infection, which makes treatment of this condition …

In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune
diseases (ADs) were published, while an international coordinated clinical programme was …

Multiple sclerosis (MS) is a common, disabling, putatively autoimmune neurological disease
with worldwide distribution. It typically begins as a relapsing disorder that later evolves to a …

Multiple sclerosis is one of the most common causes of chronic neurological disability
beginning in early to middle adult life. Multiple sclerosis is idiopathic in nature, yet …

New therapies are being evaluated by clinical trials and, if efficacious, introduced for the
treatment of adult MS. The role of these new and existing agents in the management of …

Mitoxantrone for multiple sclerosis - Martinelli Boneschi, F - 2013 | Cochrane Library Skip to
Content Cookies Our site uses cookies to improve your experience. You can find out more …

Multiple sclerosis (MS) is a CNS disorder characterized by inflammation, demyelination and
neurodegeneration, and is the most common cause of acquired nontraumatic neurological …

Multiple sclerosis (MS) is the most famous autoimmune disease attacking the central
nervous system. It attacks people from age 20–50 years old and the females' attacks double …

Importance Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune
inflammatory disorder of the central nervous system. Recently, various immunosuppressant …